HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petras, S. F. Articles by Harwood, H. J. Search for Related Content PubMed PubMed Citation Articles by Petras, S. F. Articles by Harwood, H. J., , Jr. Social Bookmarking                      What's this?

The Journal of Lipid Research, Vol. 40, 24-38, January 1999
Copyright © 1999 by Lipid Research, Inc.

Original Article

HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells

Correspondence to: H. James Harwood, Jr.

The activity of HMG-CoA reductase (HMGR) is tightly regulated, in part through post-transcriptional mechanisms that are mediated by nonsterol products of mevalonate metabolism. Previous reports have suggested that these mediators are derived from farnesyl pyrophosphate (FPP). Recent studies have implicated FPP hydrolysis products (e.g., farnesol), the squalene synthetase (SQS) reaction products presqualene pyrophosphate (PSQPP) and squalene, or their metabolites. To distinguish among these possible mediators, we evaluated the ability of HMGR and SQS inhibitors to induce compensatory increases in HMGR activity in cultured IM-9 cells. Mevinolin (HMGR inhibitor) produced predicted increases in HMGR activity that were related to the degree of cholesterolgenesis inhibition (e.g., 4-fold, 9-fold, and 17-fold increases relative to 50%, 76%, and 90% inhibition, respectively). By contrast, a variety of structurally distinct reversible, competitive, first half-reaction SQS inhibitors all reduced cholesterolgenesis by up to 90% with no appreciable increases in HMGR activity.

These observations strongly suggest that nonsterol-mediated post-transcriptional mechanisms regulating HMGR activity remain intact after SQS first half-reaction inhibition, indicating that nonsterol regulator production is independent of SQS action and ruling out PSQPP, squalene and their metabolites as possible mediators. Unexpectedly, the SQS mechanism-based irreversible inactivator, zaragozic acid A (ZGA) exhibited the greatest degree of HMGR modulation, producing 5-fold, 11-fold, and 40-fold increases in HMGR activity at concentrations that produced 25%, 50%, and 75% cholesterolgenesis inhibition, respectively. The markedly greater magnitude of HMGR stimulation by ZGA versus mevinolin at similar levels of cholesterolgenesis inhibition suggests that ZGA may directly interfere with the production or action of the nonsterol regulator.—Petras, S. F., S. Lindsey, and H. J. Harwood, Jr. HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells. J. Lipid Res. 1999. 40: 24–38.

Supplementary key words: cholesterol synthesis, HMG-CoA reductase, squalene synthetase, enzyme inhibition, metabolic regulation, cultured cells, mevinolin, zaragozic acid, farnesol, nonsterol reductase regulator

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Lee and C. D. Poulter Cloning, Solubilization, and Characterization of Squalene Synthase from Thermosynechococcus elongatus BP-1 J. Bacteriol., June 1, 2008; 190(11): 3808 - 3816. [Abstract] [Full Text] [PDF]

				H. J. Harwood Jr., S. F. Petras, D. J. Hoover, D. C. Mankowski, V. F. Soliman, E. D. Sugarman, B. Hulin, Y. Kwon, E. M. Gibbs, J. T. Mayne, et al. Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase J. Lipid Res., March 1, 2005; 46(3): 547 - 563. [Abstract] [Full Text] [PDF]

				C. E. Chandler, D. E. Wilder, J. L. Pettini, Y. E. Savoy, S. F. Petras, G. Chang, J. Vincent, and H. J. Harwood Jr. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans J. Lipid Res., October 1, 2003; 44(10): 1887 - 1901. [Abstract] [Full Text] [PDF]

				H. J. Harwood Jr., S. F. Petras, L. D. Shelly, L. M. Zaccaro, D. A. Perry, M. R. Makowski, D. M. Hargrove, K. A. Martin, W. R. Tracey, J. G. Chapman, et al. Isozyme-nonselective N-Substituted Bipiperidylcarboxamide Acetyl-CoA Carboxylase Inhibitors Reduce Tissue Malonyl-CoA Concentrations, Inhibit Fatty Acid Synthesis, and Increase Fatty Acid Oxidation in Cultured Cells and in Experimental Animals J. Biol. Chem., September 26, 2003; 278(39): 37099 - 37111. [Abstract] [Full Text] [PDF]

				K. Stamatakis, E. Cernuda-Morollon, O. Hernandez-Perera, and D. Perez-Sala Isoprenylation of RhoB Is Necessary for Its Degradation. A NOVEL DETERMINANT IN THE COMPLEX REGULATION OF RhoB EXPRESSION BY THE MEVALONATE PATHWAY J. Biol. Chem., December 13, 2002; 277(51): 49389 - 49396. [Abstract] [Full Text] [PDF]

				R. A. Zager, V. O. Shah, H. V. Shah, P. G. Zager, A. C. M. Johnson, and S. Hanson The Mevalonate Pathway during Acute Tubular Injury : Selected Determinants and Consequences Am. J. Pathol., August 1, 2002; 161(2): 681 - 692. [Abstract] [Full Text] [PDF]

				M. de la Llera-Moya, M. A. Connelly, D. Drazul, S. M. Klein, E. Favari, P. G. Yancey, D. L. Williams, and G. H. Rothblat Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL J. Lipid Res., December 1, 2001; 42(12): 1969 - 1978. [Abstract] [Full Text] [PDF]

				A. Hemmerlin and T. J. Bach Farnesol-Induced Cell Death and Stimulation of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Activity in Tobacco cv Bright Yellow-2 Cells Plant Physiology, August 1, 2000; 123(4): 1257 - 1268. [Abstract] [Full Text]

				H. Hiyoshi, M. Yanagimachi, M. Ito, I. Ohtsuka, I. Yoshida, T. Saeki, and H. Tanaka Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors J. Lipid Res., July 1, 2000; 41(7): 1136 - 1144. [Abstract] [Full Text]

				J. Pandit, D. E. Danley, G. K. Schulte, S. Mazzalupo, T. A. Pauly, C. M. Hayward, E. S. Hamanaka, J. F. Thompson, and H. J. Harwood Jr. Crystal Structure of Human Squalene Synthase. A KEY ENZYME IN CHOLESTEROL BIOSYNTHESIS J. Biol. Chem., September 22, 2000; 275(39): 30610 - 30617. [Abstract] [Full Text] [PDF]